



**World Health  
Organization**

INN Working Document 07.217 rev.  
Distrib: General  
ENGLISH ONLY  
10/01/2008

***Pre-stems\*:  
Suffixes used in the selection of INNs  
November 2007***

***Programme on International Nonproprietary Names (INN)***

***Quality Assurance and Safety: Medicines (QSM)  
Medicines Policy and Standards (PSM)  
World Health Organization,  
Geneva***

© World Health Organization (2008) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

\*The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of International onproprietary Names for Pharmaceutical Substances",2006 , WHO/PSM/QSM/2006.3). At present, they are made available for information and potential guidance to the applicants.

*stem* *definition*  
 -*suffix*  
 -*infix*-  
 New prestem is underlined. Newly promoted stem is in **bold**.

---

<i>-algron</i>	$\alpha_1$ -adrenoreceptor agonists
<i>-ampator</i>	amino-hydroxymethyl-isoxazole-propionic acid (AMPA) receptor modulators
<i>-ast</i>	<i>antiasthmatics, antiallergics, not acting primarily as antihistaminics</i>
<i>-tegr-</i>	integrin antagonists
<i>-axomab</i>	see <i>mab</i>
<i>-berel</i>	beta estrogen receptor agonists
<i>-camra</i>	intracellular adhesion molecule, ICAM-1 derivatives
<i>-casan</i>	caspase (interleukin-1b) converting enzyme inhibitors
<i>-caserin</i>	serotonin receptor agonists (mostly 5-HT <sub>2</sub> )
<i>-catib</i>	cathepsin inhibitors
<i>-ciclib</i>	cyclin dependant kinase inhibitors
<i>-ciguat</i>	guanylate cyclase activators and stimulators
<i>-closporin</i>	ciclosporin derivatives
<i>-cridar</i>	see <i>dar</i>
<i>dar</i>	<i>drugs used in multidrug resistance</i>
<i>-cri-</i>	acridinecarboxamide derivatives
<i>-ico-</i>	pipecolinate derivatives
<i>-spo-</i>	ciclosporin D derivatives
<i>-depsin</i>	depsipeptide derivatives
<i><u>-domide</u></i>	<u>antineoplastics, thalidomide derivatives</u>
<i>-dotril</i>	see <i>-tril/-trilat</i>

<i>-ectedin</i>	ecteinasidin derivatives
<i>-estrant</i>	estrogen antagonists
<i>-farnib</i>	farnesyl transferase inhibitors
<i>-fibatide</i>	see <i>tide</i>
<i>-fo-</i>	phosphoro-derivatives 224 names with infix <i>-fo-</i>
<i>-fulven</i>	antineoplastic, acylfulven derivatives
<i>-ganan</i>	antimicrobial, bactericidal permeability increasing polypeptides
<i>-gapil</i>	neuronal apoptosis inhibitors, GAPDH
<i>-icodar</i>	see <i>dar</i>
<i>-imepodib</i>	inosine monophosphate dehydrogenase inhibitors
<i>-imidar</i>	see <i>dar</i>
<i>-isant</i>	histamine-H <sub>3</sub> receptor antagonists
<i>-kalner</i>	openers of calcium-activated (maxi-K) K <sup>+</sup> -channels
<i>-leptin(e)</i>	leptin derivatives
<i>-lutamide</i>	non-steroid antiandrogens
<i>-lutril</i>	see <i>tril/trilat</i>
<i>mab</i>	<i>monoclonal antibodies</i>
<i>-axo-</i>	rat-murine hybrid antibodies
<i>-os-</i>	bone as target
<i>-ki(n)-</i>	interleukin as target
<i>-moren</i>	non-peptidic growth hormone secretagogues
<b><i>-nabant</i></b>	<b>CB cannabinoid receptor antagonists</b>
<i>-nesib</i>	kinesin inhibitors

-neurin	neurotrophins
<i>nil</i>	<i>benzodiazepine receptor antagonists/agonists</i>
-punil	mitochondrial benzodiazepine receptor (MBR)- selective agonists also partial or inverse (purine derivatives)
-osuran	urotensin receptor antagonists
-otilate	hepatoprotectants, diisopropyl-1,3-dithiol-malonate derivatives
-parib	Poly-ADP-Ribose polymerase inhibitors
-patril/-patrilat	see <i>tril/trilat</i>
-peg/-pegil ?	is to be considered for future pegylated compounds (i.e. substances linked covalently to polyethylene glycol)
-plasinin	inhibitors of Plasminogen Activator Inhibitors-type1(PAI-1)
-prazan	proton pump inhibitors, not depended on acid activation
-prinin	nootropic agents, purine derivatives
-punil	see <i>nil</i>
-spodar	see <i>dar</i>
-siban	oxytocin antagonists
-sulind	antineoplastics, sulindac metabolites
-stinel	<i>N</i> -methyl-D-aspartatic acid (NMDA) receptor antagonist, glycine recognition site
-tapide	Microsomal Triglyceride Transfer Protein (MTP) inhibitors
-tegrast	see <i>ast</i>
-tegravir	see <i>vir</i>
-texafin	texaphyrin derivatives
<i>tide</i>	<i>peptides and glycopeptides</i>
-fiba-	platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist)
-tirome	antihyperlidaemic; thyromimetic derivatives

<i>-trombopag</i>	thrombopoietin agonists
<i>tril/trilat</i>	<i>endopeptidase inhibitors</i>
<i>-dotril</i>	no definition
<i>-lutril</i>	NEP (Neutral Endopeptidase) inhibitor possessing additional ECE (endothelin converting enzyme) inhibitory activity
<i>-patril/-patrilat</i>	ACE (angiotensin-I Converting Enzyme) and NEP (Neutral Endopeptidase) inhibitors
<i>-uclin</i>	mucosal tolerance inductors
<i>vir</i>	<i>antivirals (undefined group)</i>
<i>-tegravir</i>	HIV integrase inhibitors
<i>-virenz</i>	benzoxazinone derivatives

\* \* \*